BR112021004776A2 - Métodos para tratamento de hipertrofia do músculo masseter - Google Patents

Métodos para tratamento de hipertrofia do músculo masseter

Info

Publication number
BR112021004776A2
BR112021004776A2 BR112021004776A BR112021004776A BR112021004776A2 BR 112021004776 A2 BR112021004776 A2 BR 112021004776A2 BR 112021004776 A BR112021004776 A BR 112021004776A BR 112021004776 A BR112021004776 A BR 112021004776A BR 112021004776 A2 BR112021004776 A2 BR 112021004776A2
Authority
BR
Brazil
Prior art keywords
methods
masseter muscle
treating
muscle hypertrophy
masseter
Prior art date
Application number
BR112021004776A
Other languages
English (en)
Portuguese (pt)
Inventor
Beta Bowen
Christine Somogyi
Elisabeth Lee
D Rogers John
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112021004776A2 publication Critical patent/BR112021004776A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Traffic Control Systems (AREA)
BR112021004776A 2018-09-13 2019-09-12 Métodos para tratamento de hipertrofia do músculo masseter BR112021004776A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731064P 2018-09-13 2018-09-13
PCT/US2019/050910 WO2020056204A1 (en) 2018-09-13 2019-09-12 Methods for treatment of masseter muscle hypertrophy

Publications (1)

Publication Number Publication Date
BR112021004776A2 true BR112021004776A2 (pt) 2021-11-09

Family

ID=68069888

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021004776A BR112021004776A2 (pt) 2018-09-13 2019-09-12 Métodos para tratamento de hipertrofia do músculo masseter

Country Status (11)

Country Link
US (3) US20200085923A1 (https=)
EP (1) EP3849585A1 (https=)
JP (2) JP2022500417A (https=)
KR (1) KR20210057106A (https=)
CN (1) CN112955166A (https=)
AU (2) AU2019337656A1 (https=)
BR (1) BR112021004776A2 (https=)
CA (1) CA3112227A1 (https=)
MX (1) MX2021002993A (https=)
TW (2) TW202434280A (https=)
WO (1) WO2020056204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152107A (ko) * 2021-02-26 2023-11-02 이온 바이오파마, 인크. 두통을 치료하는 데 사용하기 위한 신경독소 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3368071B1 (en) * 2015-10-29 2022-01-26 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
WO2020056204A1 (en) 2020-03-19
KR20210057106A (ko) 2021-05-20
EP3849585A1 (en) 2021-07-21
MX2021002993A (es) 2021-08-11
JP2024177185A (ja) 2024-12-19
TW202023606A (zh) 2020-07-01
AU2025226702A1 (en) 2025-09-25
TWI835858B (zh) 2024-03-21
US20200085923A1 (en) 2020-03-19
US20230080740A1 (en) 2023-03-16
JP2022500417A (ja) 2022-01-04
TW202434280A (zh) 2024-09-01
AU2019337656A1 (en) 2021-05-06
CN112955166A (zh) 2021-06-11
CA3112227A1 (en) 2020-03-19
US20230083250A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
EP4338804A3 (en) Epinephrine spray formulations
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112021021921A2 (pt) Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
MX395076B (es) COMPOSICIÓN A BASE DE UN EXTRACTO DE BIOACTIVO DE L. fermentum PARA USARSE EN EL TRATAMIENTO DE CONDICIONES DERMATOLOGICAS HUMANAS.
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
BR112021024634A2 (pt) Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
BR112016025333A2 (pt) agente, produto e uso
MX394918B (es) Neurotoxinas botulinas para uso en terapia
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
MX2022005215A (es) Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1).
UY38352A (es) Inhibidores de integrina alfavbeta6
PH12019502721A1 (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
JOP20210008A1 (ar) أنواع أبيراز مذابة، وطرق لاستخدامها
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2019236765A8 (en) Acylated catechin polyphenols and methods of their use for the treatment of cancer
BR112018072664A2 (pt) composições e métodos para tratamento de inflamação e infecção do olho
BR112021004776A2 (pt) Métodos para tratamento de hipertrofia do músculo masseter
MX369163B (es) Composiciones topicas que contienen glicosaminoglicanos reticulados.
MX2020010338A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.